...
首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
【24h】

Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.

机译:伊立替康和阿霉素联合化疗治疗难治性和复发性非霍奇金淋巴瘤。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma were treated by combination chemotherapy with irinotecan hydrochloride (CPT-11) and adriamycin (ADM): CPT-11, 25 mg/m2 on days 1 and 2; ADM, 40 mg/m2 on day 3. Nine (36%) of twenty-five patients achieved CR. Fairly good responses were seen in relapsed B-cell lymphomas (4 of 8 in diffuse large B-cell lymphoma and 2 of 2 in follicular lymphoma grade 1), and substantial responses in T-cell lymphomas (1 of 4 in peripheral T-cell lymphoma and 2 of 7 in adult T-cell leukemia/lymphoma). Leukopenia was frequent but tolerable, and diarrhea minimal. Combination chemotherapy with a reduced dose CPT-11 and ADM was useful in the treatment of relapsed non-Hodgkin's lymphoma.
机译:25例复发或难治性非霍奇金淋巴瘤患者在第1天和第2天接受联合盐酸伊立替康(CPT-11)和阿霉素(ADM)CPT-11联合化疗,治疗剂量为25 mg / m2;在第3天,ADM为40 mg /m2。25名患者中有9名(36%)达到了CR。在复发性B细胞淋巴瘤(在弥漫性大B细胞淋巴瘤中,每8个中有4个,在1级滤泡性淋巴瘤中,有2个中的2个)中观察到相当好的反应,而在T细胞淋巴瘤中,在外周T细胞中,有4个中有1个反应良好。成人T细胞白血病/淋巴瘤中有7个淋巴瘤和2个)。白细胞减少症很常见但可以忍受,腹泻很少。降低剂量的CPT-11和ADM联合化疗可用于治疗复发性非霍奇金淋巴瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号